Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genome, Viral | 1 | 2021 | 12 | 0.680 |
Why?
|
| Transcription, Genetic | 2 | 2013 | 140 | 0.430 |
Why?
|
| Drug Discovery | 1 | 2013 | 38 | 0.400 |
Why?
|
| Neoplasms | 3 | 2020 | 754 | 0.400 |
Why?
|
| Brain Neoplasms | 5 | 2022 | 637 | 0.360 |
Why?
|
| Antineoplastic Agents | 2 | 2011 | 595 | 0.310 |
Why?
|
| Appendiceal Neoplasms | 2 | 2020 | 99 | 0.290 |
Why?
|
| Peritoneal Neoplasms | 2 | 2020 | 256 | 0.250 |
Why?
|
| Glioblastoma | 2 | 2022 | 159 | 0.250 |
Why?
|
| Computational Biology | 5 | 2020 | 99 | 0.250 |
Why?
|
| Humans | 24 | 2024 | 32282 | 0.250 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 443 | 0.240 |
Why?
|
| Models, Biological | 4 | 2017 | 408 | 0.230 |
Why?
|
| Mice | 10 | 2024 | 2571 | 0.230 |
Why?
|
| Cell Line, Tumor | 7 | 2024 | 729 | 0.220 |
Why?
|
| Clofazimine | 1 | 2024 | 1 | 0.210 |
Why?
|
| Animals | 12 | 2024 | 8199 | 0.200 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2024 | 99 | 0.200 |
Why?
|
| Systems Biology | 2 | 2016 | 10 | 0.190 |
Why?
|
| Gene Regulatory Networks | 2 | 2020 | 45 | 0.170 |
Why?
|
| Glioma | 1 | 2022 | 137 | 0.160 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 1158 | 0.160 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2020 | 28 | 0.150 |
Why?
|
| Software | 3 | 2019 | 124 | 0.150 |
Why?
|
| Magnetic Field Therapy | 1 | 2019 | 15 | 0.150 |
Why?
|
| Lymphopoiesis | 1 | 2019 | 4 | 0.150 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2019 | 8 | 0.150 |
Why?
|
| Bone Neoplasms | 2 | 2018 | 117 | 0.150 |
Why?
|
| Interleukin-4 | 1 | 2019 | 22 | 0.150 |
Why?
|
| Calcium Channels, T-Type | 1 | 2019 | 28 | 0.150 |
Why?
|
| Interleukin-1beta | 1 | 2019 | 42 | 0.150 |
Why?
|
| Signal Transduction | 4 | 2019 | 727 | 0.150 |
Why?
|
| Myeloid Cells | 1 | 2019 | 39 | 0.140 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 65 | 0.140 |
Why?
|
| Transforming Growth Factor beta | 1 | 2019 | 63 | 0.140 |
Why?
|
| Breast Neoplasms | 3 | 2018 | 762 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2018 | 19 | 0.140 |
Why?
|
| Microfilament Proteins | 1 | 2018 | 37 | 0.140 |
Why?
|
| Neoplastic Stem Cells | 2 | 2019 | 96 | 0.140 |
Why?
|
| STAT3 Transcription Factor | 1 | 2018 | 23 | 0.140 |
Why?
|
| Microglia | 1 | 2018 | 67 | 0.130 |
Why?
|
| Protein Interaction Mapping | 1 | 2017 | 11 | 0.130 |
Why?
|
| Exosomes | 1 | 2018 | 43 | 0.130 |
Why?
|
| Incidence | 1 | 2021 | 1241 | 0.130 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 164 | 0.130 |
Why?
|
| Receptor, erbB-2 | 1 | 2018 | 63 | 0.130 |
Why?
|
| Hematologic Diseases | 1 | 2017 | 20 | 0.130 |
Why?
|
| Calcium | 1 | 2019 | 339 | 0.130 |
Why?
|
| Models, Statistical | 1 | 2017 | 187 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2018 | 181 | 0.120 |
Why?
|
| Female | 12 | 2024 | 19945 | 0.120 |
Why?
|
| Pharmaceutical Preparations | 2 | 2013 | 38 | 0.120 |
Why?
|
| Cell Line | 4 | 2020 | 454 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 131 | 0.120 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 211 | 0.120 |
Why?
|
| Models, Genetic | 1 | 2015 | 93 | 0.110 |
Why?
|
| Janus Kinase 2 | 1 | 2014 | 6 | 0.110 |
Why?
|
| Chloroquine | 1 | 2014 | 3 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 298 | 0.110 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 109 | 0.110 |
Why?
|
| Transcription Factors | 1 | 2015 | 183 | 0.100 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 70 | 0.100 |
Why?
|
| Pharmacology | 1 | 2013 | 6 | 0.100 |
Why?
|
| Drug Industry | 1 | 2013 | 16 | 0.100 |
Why?
|
| Drug Delivery Systems | 1 | 2013 | 104 | 0.100 |
Why?
|
| Brain | 2 | 2018 | 965 | 0.090 |
Why?
|
| Gene Expression Profiling | 3 | 2020 | 315 | 0.090 |
Why?
|
| Immunotherapy | 2 | 2024 | 91 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2011 | 11 | 0.080 |
Why?
|
| Prognosis | 3 | 2020 | 1534 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 90 | 0.080 |
Why?
|
| Alzheimer Disease | 1 | 2013 | 280 | 0.080 |
Why?
|
| Mice, Nude | 3 | 2018 | 285 | 0.080 |
Why?
|
| Cell Proliferation | 3 | 2018 | 603 | 0.070 |
Why?
|
| Mass Spectrometry | 1 | 2008 | 98 | 0.070 |
Why?
|
| Survival Rate | 2 | 2020 | 893 | 0.070 |
Why?
|
| Sulfides | 2 | 2018 | 27 | 0.070 |
Why?
|
| Caprylates | 2 | 2018 | 27 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2018 | 193 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2018 | 258 | 0.060 |
Why?
|
| Aged | 4 | 2020 | 10263 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 2 | 2020 | 196 | 0.060 |
Why?
|
| Middle Aged | 4 | 2020 | 11851 | 0.060 |
Why?
|
| Phenotype | 2 | 2019 | 622 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2016 | 222 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 1083 | 0.050 |
Why?
|
| Adult | 3 | 2020 | 9259 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 2 | 2013 | 65 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 2 | 2013 | 75 | 0.050 |
Why?
|
| Ubiquitination | 1 | 2022 | 15 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2022 | 32 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2022 | 64 | 0.040 |
Why?
|
| Male | 4 | 2020 | 19441 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2024 | 792 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2019 | 3416 | 0.040 |
Why?
|
| Co-Repressor Proteins | 1 | 2020 | 3 | 0.040 |
Why?
|
| Immune System Phenomena | 1 | 2020 | 5 | 0.040 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2020 | 15 | 0.040 |
Why?
|
| Oncogenes | 1 | 2020 | 14 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2020 | 53 | 0.040 |
Why?
|
| Interleukin-9 | 1 | 2019 | 1 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 2019 | 53 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2019 | 80 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 79 | 0.040 |
Why?
|
| Melanoma, Experimental | 1 | 2019 | 10 | 0.040 |
Why?
|
| Interleukin-1 | 1 | 2019 | 48 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 24 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 114 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2019 | 37 | 0.040 |
Why?
|
| Radiometry | 1 | 2019 | 52 | 0.040 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2020 | 154 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2019 | 112 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 555 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2019 | 84 | 0.040 |
Why?
|
| Genomics | 1 | 2019 | 89 | 0.040 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2018 | 5 | 0.030 |
Why?
|
| Cell Respiration | 1 | 2018 | 20 | 0.030 |
Why?
|
| Mitoxantrone | 1 | 2018 | 20 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2018 | 32 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2018 | 131 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2018 | 73 | 0.030 |
Why?
|
| Retreatment | 1 | 2018 | 42 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2018 | 36 | 0.030 |
Why?
|
| Cytarabine | 1 | 2018 | 59 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 773 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2018 | 52 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2018 | 68 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 2018 | 67 | 0.030 |
Why?
|
| Sensation Disorders | 1 | 2017 | 11 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2018 | 250 | 0.030 |
Why?
|
| Lymphopenia | 1 | 2017 | 11 | 0.030 |
Why?
|
| Leucovorin | 1 | 2017 | 19 | 0.030 |
Why?
|
| Hypokalemia | 1 | 2017 | 16 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 30 | 0.030 |
Why?
|
| Neutropenia | 1 | 2017 | 24 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2018 | 141 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 106 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2017 | 62 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2017 | 82 | 0.030 |
Why?
|
| Hypoalbuminemia | 1 | 2017 | 13 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 41 | 0.030 |
Why?
|
| Camptothecin | 1 | 2017 | 45 | 0.030 |
Why?
|
| Recurrence | 1 | 2018 | 285 | 0.030 |
Why?
|
| Abdominal Pain | 1 | 2017 | 44 | 0.030 |
Why?
|
| Anemia | 1 | 2017 | 50 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 252 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2017 | 79 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2017 | 85 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 477 | 0.030 |
Why?
|
| Mutation | 1 | 2019 | 497 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2019 | 461 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2018 | 243 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 461 | 0.030 |
Why?
|
| Mitochondria | 1 | 2018 | 211 | 0.030 |
Why?
|
| Sepsis | 1 | 2017 | 164 | 0.030 |
Why?
|
| Transcription Initiation Site | 1 | 2015 | 10 | 0.030 |
Why?
|
| Histones | 1 | 2015 | 50 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2016 | 139 | 0.030 |
Why?
|
| Protein Binding | 1 | 2015 | 244 | 0.030 |
Why?
|
| Genome, Human | 1 | 2015 | 130 | 0.030 |
Why?
|
| Autophagy | 1 | 2014 | 55 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2013 | 20 | 0.030 |
Why?
|
| Astrocytes | 1 | 2013 | 61 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 74 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 60 | 0.020 |
Why?
|
| Technology, Pharmaceutical | 1 | 2013 | 3 | 0.020 |
Why?
|
| Computer Graphics | 1 | 2013 | 10 | 0.020 |
Why?
|
| Automation | 1 | 2013 | 28 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2013 | 93 | 0.020 |
Why?
|
| Drug Design | 1 | 2013 | 51 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2013 | 52 | 0.020 |
Why?
|
| Cell Movement | 1 | 2013 | 167 | 0.020 |
Why?
|
| RNA Interference | 1 | 2013 | 78 | 0.020 |
Why?
|
| Artificial Intelligence | 1 | 2013 | 63 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2020 | 3626 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 232 | 0.020 |
Why?
|
| Internet | 1 | 2013 | 202 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2013 | 854 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 478 | 0.020 |
Why?
|
| Aminoacetonitrile | 1 | 2011 | 1 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 2649 | 0.020 |
Why?
|
| Sirolimus | 1 | 2011 | 34 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 180 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 423 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 717 | 0.020 |
Why?
|
| United States | 1 | 2013 | 4072 | 0.010 |
Why?
|